 |
English
|
正體中文
|
简体中文
|
全文筆數/總筆數 : 29490/55136 (53%)
造訪人次 : 1522933
線上人數 : 403
|
|
|
資料載入中.....
|
請使用永久網址來引用或連結此文件:
http://ir.cmu.edu.tw/ir/handle/310903500/30884
|
| 題名: | Effect of CDA-II on cell viability, lipid peroxidation, glutathione concentration and its related enzyme activities in primary rat hepatocytes |
| 作者: | Lin, WC;Liao, YC;Liau, MC;Sheen, LY |
| 貢獻者: | 醫學院醫學系藥理學科;Natl Taiwan Univ, Grad Inst Food Sci & Technol, Taipei 106, Taiwan;China Med Coll, Dept Pharmacol, Taichung, Taiwan;China Med Coll, Grad Inst Chinese Pharmaceut Sci, Taichung, Taiwan;China Med Coll, Grad Inst Pharmaceut Chem, Taichung, Taiwan |
| 日期: | 2003 |
| 上傳時間: | 2010-09-24 15:04:18 (UTC+8) |
| 出版者: | WORLD SCIENTIFIC PUBL CO PTE LTD |
| 摘要: | Objectives. To use the Bst U I polymorphism as a genetic marker in the search for the association between patients with prostate cancer and normal control subjects. The formation or progression of prostate cancer is presumed to be associated with a polymorphism of the vascular endothelial growth factor (VEGF) gene. The most frequently seen polymorphism is Bst U I (C to T) located at the -460th nucleotide upstream of the VEGF gene. Methods. A normal control group of 119 healthy people and 96 patients with prostate cancer were examined. The polymorphism was seen after polymerase chain reaction-based restriction analysis. Results. The analysis revealed significant differences between normal individuals and patients with cancer (P < 0.001). Also, the distribution of the "TT" homozygote in the patient group was greater than that in the control group. The odds ratio per copy of the "T" allele was 2.3 (95% confidence interval 1.4 to 3.8) and was 2.2 (95% CI 1.3 to 3.8) when adjusted for age. No statistically significant differences in clinical stage or grade were found. We also categorized the 54 patients who received hormonal therapy into response and nonresponse groups, but no statistically significant differences between these two groups were revealed (P = 0.110, Fisher's exact test). Conclusions. The Bst U I polymorphism of the VEGF gene is a suitable genetic marker of prostate cancer but cannot be used in the prediction of the outcome of patients who have received hormonal therapy. |
| 關聯: | AMERICAN JOURNAL OF CHINESE MEDICINE 31(3):415-423 |
| 顯示於類別: | [醫學系] 期刊論文
|
在CMUR中所有的資料項目都受到原著作權保護.
|
